Strategic manufacturing partnership supports late-stage development of promising immunotherapy drug
Basel, 9 April 2026 – ImmuneOncia Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Lonza, a global contract development and manufacturing organization, to support the late-stage clinical supply of its cancer drug candidate, Danburstotug (IMC-001).
Danburstotug is a fully human monoclonal antibody designed to help the immune system fight cancer. It works as an immune checkpoint inhibitor, targeting PD-L1, a protein that allows cancer cells to escape detection. The drug is currently being studied for the treatment of relapsed or refractory NK/T-cell lymphoma, a rare and aggressive type of cancer.
Under this agreement, Lonza will handle both development and manufacturing processes. The drug substance will be produced at Lonza’s facility in Slough, United Kingdom, while drug product development and manufacturing will take place at its sites in Basel and Stein, Switzerland.
In simple terms, ImmuneOncia is relying on Lonza’s expertise to ensure that the drug is produced safely, efficiently, and ready for late-stage clinical trials and potential commercial use. Lonza’s integrated approach, which combines drug development and manufacturing under one network, helps speed up the process and maintain high-quality standards.
This collaboration is an important step for ImmuneOncia as it aims for early approval of Danburstotug, particularly for treating rare cancers like NK/T-cell lymphoma. The partnership also strengthens the company’s position for future global licensing opportunities and expansion into international markets.
For Lonza, the agreement reflects its continued role in supporting biotech companies throughout their development journey, from early-stage research to commercialization. By providing end-to-end manufacturing solutions, Lonza enables companies like ImmuneOncia to focus more on innovation and clinical progress.
As demand for advanced cancer therapies grows, partnerships like this highlight the importance of combining scientific innovation with strong manufacturing capabilities. With immunotherapy and targeted treatments gaining momentum, Danburstotug could become a significant addition to the evolving landscape of cancer care.
